Therapieresistente seronegative Polyarthritis mit ungewöhnlichem Verlauf bei systemischer Manifestation
Johannes Olschner, Julius Joos, Britta Besemer, Matthias Hahn et autres
0 citationsGerman Medical Science (German Research Foundation)
Britta Besemer
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
157Publications signalées
3826Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsCAR-T cell therapy researchPeptidase Inhibition and AnalysisCancer Treatment and Pharmacology
Publications récentes
The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022
Claire Comerford, Patrick Hayden, Diderik‐Jan Eikema, Linda Koster et autres
0 citationsBritish Journal of Haematology
Multiples Myelom
0 citationsDMW - Deutsche Medizinische Wochenschrift
MM-349: Teclistamab Plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk
Rahul Banerjee, Niels WCJ van de Donk, Roberto Mina, María-Victoria Mateos et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: MM-349: Teclistamab Plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk
Rahul Banerjee, Niels WCJ van de Donk, Roberto Mina, María-Victoria Mateos et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R. Ginde, Stefanie Huhn, Philipp Reichert et autres
1 citationJournal of Clinical Oncology
Plenary Abstracts Session & Oral Presentations
Rahul Banerjee, Niels W C J van de Donk, Roberto Mina, Maria-Victoria Mateos et autres
0 citationsUniversity of Southern Denmark Research Portal (University of Southern Denmark)
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R. Ginde, Stefanie Huhn, Philipp Reichert et autres
0 citationsJournal of Clinical Oncology
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis
Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, Ashutosh D. Wechalekar et autres
2 citationsBlood
Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma
Martin Pietzsch, Sina Beer, Lucca M. Kimmich, Chiara Windsor et autres
0 citationsHaematologica
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study
Robert Z. Orlowski, Meletios A. Dimopoulos, Xavier Leleu, T. Facon et autres
2 citationsBlood
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka et autres
79 citationsNew England Journal of Medicine
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.